Jonathan Chou
@jonchou05
Followers
100
Following
149
Media
1
Statuses
57
Thanks to @UCSFCancer for covering our study which showed that a PPARg agonist rosiglitazone (an old diabetes drug) can modulate NECTIN4 & enhance activity of a new CAR T in #bladdercancer @CChuMD @koshkin85 @DrTFriedlander @SimaPorten @UCSFUrology
ucsf.edu
Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC...
0
3
9
Research funded in part by BCAN with @jonchou05 in @NatureComms : Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Click here to read the article:
nature.com
Nature Communications - Enfortumab vedotin (EV) is the current standard treatment for advanced bladder cancer, but resistance typically develops within a year, highlighting the need for new...
2
9
23
In @naturecomms: Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Click here to read the article:
nature.com
Nature Communications - Single cell analysis of histologic variant bladder tumors detects a shared CA125+ tumor cell state associated with aggressive clinical features and reveals enriched...
0
1
3
UCSF BCAN community really showed up for our walk this year, babies and 4 legged friends alike, to support our patients with bladder CA and raising $40k for research. No one walks alone 🧡@bcan_chisolm @UCSFCancer @UCSFUrology
@SimaPorten @jonchou05 @koshkin85 @SamWashUro
0
4
17
📢Check out this Article NOW ONLINE! @NatureCancer '#Transcription and #DNAreplication collisions lead to large tandem duplications and expose targetable #therapeutic vulnerabilities in #cancer' ✏️By Jonathan Chou, Lixing Yang and colleagues 📎 https://t.co/MyQVvgPWsq
0
6
7
🔥 Hot off the press: Lixing Yang, PhD, and collaborators at @UCSF have published a ground breaking work in @NatureCancer, demonstrating how unrepaired collision of DNA replication and transcription can drive aggressive cancers. @UChicagoCCB @jonchou05
https://t.co/YLKqGCat5I
0
3
4
📕 New publication alert: Lixing Yang, PhD and his collaborators at @UCSF published an exciting work demonstrating new approaches to correct the errors generated by the collision of DNA replication and transcription. @jonchou05 @NatureCancer @UChicagoCCB
https://t.co/Gg39yK3M5K
1
2
4
In prostate cancer, sensitivity to poly ADP-ribose polymerase inhibitors is dependent on the specific type and zygosity of the CDK12 mutation, reports Dr. Jonathan Chou's team at @UCSF. https://t.co/qRdFVgfLZ9
0
3
8
Thanks @jonchou05 for visiting @fredhutch fantastic talk & dinner! @HsiehLab @li_haolong @DrOmarMian @JLWrightMD @koshkin85 @GavinHa @DrTFriedlander @BladderCancerUS @Uromigos @JoshMeeks @TiansterZhang @jklee_lab @FaltasLab Great opportunities for collaboration & translation!
Thank you @jonchou05 from @UCSFCancer for presenting your innovative work @fredhutch on understanding and targeting the surface-ome in #bladdercancer. @PGrivasMDPhD @li_haolong @DrOmarMian @JLWrightMD
1
2
11
2
5
38
Histologic variants in bladder cancer harbor aggressive molecular features including TM4SF1 expression and a CA125+ cell state https://t.co/wBicWEkw1q
#biorxiv_cancer
0
2
0
We are happy to share our new study published today @JCO_ASCO (👉 https://t.co/NJtUVRVJ0Q) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered
13
48
147
@scserendipity1 @JCO_ASCO @PTarantinoMD @ASCO @urotoday @OncoAlert @imedverse @Markuseckstein3 Thanks @scserendipity1 We and others ( https://t.co/S9WIFrv8vF) believe yes: Membranous NECTIN4 expression is correlated to EV response. Further, app. 40% of oUC metastatic samples are lacking membranous NECTIN4
aacrjournals.org
AbstractPurpose:. The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients...
1
5
6
Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma - @PTarantinoMD
@niklas_kluemper
#BreastCancer #DanaFarberCancerInstitute #GU24 #HER2 #ExperimentalOncology #LungCancer
https://t.co/C4pVDLIgTH
oncodaily.com
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma / Antibody drug conjugates, Breast Cancer,
0
5
10
Great overview on UC pathology @Markuseckstein3 🔥 important to keep these pathways of UC carcinogenesis in mind for ADC targets as well, as NECTIN4 is overexpressed in luminal tumors as nicely demonstrated by @jonchou05
https://t.co/y9gkotHqZY in @CCR_AACR @urotoday @OncoAlert
pubmed.ncbi.nlm.nih.gov
Sensitivity to EV is mediated by expression of NECTIN4, which is enriched in luminal subtypes of bladder cancer. These findings may have implications for biomarker development, patient selection, and...
In the first part we tried to understand the architecture of regular urothelium and key markers expressed in different layers of it. This important to understand why urothelial cancer can appear with multiple molecular and histological subtypes.
0
7
10
Our latest paper ist out in @Histo_Journal ! We comprehensively studied the membranous protein expression of the two important #ADC targets TROP2 and NECTIN4 (surfaceome 🏄♂️). it is the first paper on protein expression in a large cohort of over 200 muscle-invasive and metastic
2
12
34
Awesome showing by @UCSFCancer at #BCANTT23 Thank you to @SimaPorten and many of our colleagues @UCSFHospitals including also @friedt02 @Tanjin097 @jonchou05 @xiaolin_zhu @HemoncUcsf @ckcding and our NPs Iva Colon and Krisztina Emodi @BladderCancerUS
Team UCSF at the 2023 BCAN Think Tank! Blessed to have such amazing colleagues and friends @CChuMD @koshkin85 @ckcding @SamWashUro @HeikoYangMDPhD #BCANTT23
0
2
16
Team UCSF at the 2023 BCAN Think Tank! Blessed to have such amazing colleagues and friends @CChuMD @koshkin85 @ckcding @SamWashUro @HeikoYangMDPhD #BCANTT23
0
6
49
Excited to see our B7-H3 paper published by STM today! Many thanks for all lab members, collaborators and funding sources! @Wei_Shi90 @BradStCroix @aaparicioMD @MDAndersonNews @PCFnews @CPRITTexas @NIH
science.org
Immune checkpoint B7-H3 is a promising therapeutic target in PTEN/p53-deficient prostate cancer.
9
7
35
Exciting new study out of @UCSFCancer Michael Evans @jonchou05 et al: Theranostic Targeting of CDCP1 in Multiple Subtypes of Bladder Cancer with Lu177 https://t.co/5EPd0BMRCf
0
5
25